# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
According to a new poll conducted by Hill-HarrisX, 65% of registered voters say psychedelic substances do not have medical use.
Cybin (NYSE: CYBN), a biotech company in the psychedelics space, began listing its stock on the New York Stock Exchange on Thur...
This article was made possible thanks to invaluable research by Michael Haichin and Josh Hardman from Psilocybin Alpha. In jus...
Last week in Psychedelics:
HC Wainwright & Co. analyst Patrick Trucchio initiates coverage on Cybin (OTC:CLXPF) with a Buy rating and announces Pri...
Cybin Inc.
Excitement around psychedelics grows as major U.S. exchanges make room for more companies in the sector.
Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF), a biotech company in the psychedelics space, announced on Thursday a conditional approva...